Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Pariente
Edouard Louis

Showing results (171-180 of 364) with videos related to

Pageof 37
Sort By:
European Journal of Gastroenterology & Hepatology|July 28, 2018
Oral vancomycin induces sustained deep remission in adult patients with ulcerative colitis and primary sclerosing cholangitisGuillaume Pineton de Chambrun, Maria Nachury, Natalie Funakoshi, et al.
Gut|August 25, 2022
Distinct blood protein profiles associated with the risk of short-term and mid/long-term clinical relapse in patients with Crohn's disease stopping infliximab: when the remission state hides different types of residual disease activityNicolas Pierre, Vân Anh Huynh-Thu, Thomas Marichal, et al.
Pharmacogenetics and Genomics|September 27, 2006
The TNF/ADAM 17 system: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's diseaseVinciane Dideberg, Emilie Théâtre, Frédéric Farnir, et al.
Advances in Therapy|August 6, 2024
Content Validity and Psychometric Evaluation of the Crohn's Symptom Severity (CSS) Questionnaire in Patients with Moderately to Severely Active Crohn's DiseaseEdouard Louis, Wan-Ju Lee, Leighann Litcher-Kelly, et al.
The American Journal of Gastroenterology|May 5, 2026
Improvement in Health-Related Quality of Life in Patients With Moderate to Severe Crohn's Disease Treated With Risankizumab Versus Ustekinumab in the Phase 3B SEQUENCE StudyEdward V Loftus, Namita Joshi, Bruce E Sands, et al.
Gastroenterology|May 24, 2011
Activation of the receptor NKG2D leads to production of Th17 cytokines in CD4+ T cells of patients with Crohn's diseaseBenjamin Pariente, Iulia Mocan, Matthieu Camus, et al.
Digestive Diseases and Sciences|December 8, 2019
Radiological Response Is Associated with Better Outcomes and Should Be Considered a Therapeutic Target in Crohn's DiseaseEléonore Hallé, Mustapha Azahaf, Nicolas Duveau, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 24, 2020
Variation of faecal calprotectin level within the first three months after bowel resection is predictive of endoscopic postoperative recurrence in Crohn's diseaseMathilde Boube, David Laharie, Stéphane Nancey, et al.
Alimentary Pharmacology & Therapeutics|October 8, 2019
Fine-scale geographical distribution and ecological risk factors for Crohn's disease in France (2007-2014)Michaël Genin, Mathurin Fumery, Florent Occelli, et al.
Inflammatory Bowel Diseases|May 21, 2016
Natural History of Crohn's Disease in Elderly Patients Diagnosed Over the Age of 70 Years: A Population-Based StudyMathurin Fumery, Benjamin Pariente, Helene Sarter, et al.
Pageof 37

Showing results (171-180 of 364) with videos related to

Sort By:
Pageof 37
European Journal of Gastroenterology & Hepatology|July 28, 2018
Oral vancomycin induces sustained deep remission in adult patients with ulcerative colitis and primary sclerosing cholangitisGuillaume Pineton de Chambrun, Maria Nachury, Natalie Funakoshi, et al.
Gut|August 25, 2022
Distinct blood protein profiles associated with the risk of short-term and mid/long-term clinical relapse in patients with Crohn's disease stopping infliximab: when the remission state hides different types of residual disease activityNicolas Pierre, Vân Anh Huynh-Thu, Thomas Marichal, et al.
Pharmacogenetics and Genomics|September 27, 2006
The TNF/ADAM 17 system: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's diseaseVinciane Dideberg, Emilie Théâtre, Frédéric Farnir, et al.
Advances in Therapy|August 6, 2024
Content Validity and Psychometric Evaluation of the Crohn's Symptom Severity (CSS) Questionnaire in Patients with Moderately to Severely Active Crohn's DiseaseEdouard Louis, Wan-Ju Lee, Leighann Litcher-Kelly, et al.
The American Journal of Gastroenterology|May 5, 2026
Improvement in Health-Related Quality of Life in Patients With Moderate to Severe Crohn's Disease Treated With Risankizumab Versus Ustekinumab in the Phase 3B SEQUENCE StudyEdward V Loftus, Namita Joshi, Bruce E Sands, et al.
Gastroenterology|May 24, 2011
Activation of the receptor NKG2D leads to production of Th17 cytokines in CD4+ T cells of patients with Crohn's diseaseBenjamin Pariente, Iulia Mocan, Matthieu Camus, et al.
Digestive Diseases and Sciences|December 8, 2019
Radiological Response Is Associated with Better Outcomes and Should Be Considered a Therapeutic Target in Crohn's DiseaseEléonore Hallé, Mustapha Azahaf, Nicolas Duveau, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 24, 2020
Variation of faecal calprotectin level within the first three months after bowel resection is predictive of endoscopic postoperative recurrence in Crohn's diseaseMathilde Boube, David Laharie, Stéphane Nancey, et al.
Alimentary Pharmacology & Therapeutics|October 8, 2019
Fine-scale geographical distribution and ecological risk factors for Crohn's disease in France (2007-2014)Michaël Genin, Mathurin Fumery, Florent Occelli, et al.
Inflammatory Bowel Diseases|May 21, 2016
Natural History of Crohn's Disease in Elderly Patients Diagnosed Over the Age of 70 Years: A Population-Based StudyMathurin Fumery, Benjamin Pariente, Helene Sarter, et al.
Pageof 37